1. OP0227 A Randomized Double-Blind Treatment Strategy Study Evaluating Continuation or Reduced-Frequency Dosing of Certolizumab Pegol versus Withdrawal To Maintain Low Disease Activity in Early RA Patients (C-Early Period 2). (15th July 2016) Authors: Emery, P.; Bingham, C.; Burmester, G.-R.; Bykerk, V.P.; Furst, D.; Mariette, X.; van der Heijde, D.; van Vollenhoven, R.; VanLunen, B.; Ecoffet, C.; Cioffi, C.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗